Clinical Trial Details

Overview

Research Study Summary

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

Purpose
This study is being conducted to demonstrate that perampanel given as adjunctive anti-epileptic treatment is superior to placebo in reducing the number of drop seizures in participants with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS).
To Learn more

CW ID: 223045
Date Last Changed: February 8, 2017

Clinical Trial Snapshot

Gender
Both Male and Female
Age
2 and up
Overall Status
Recruiting
Lead Sponsor
Eisai Inc
Facility Type
N/A

Eligibility

Inclusion Criteria:

Participants must have a diagnosis of Lennox-Gastaut Syndrome (LGS) as evidenced by:

  • more than one type of generalized seizure, including drop seizures (atonic, tonic, or myoclonic) for at least 6 months before Visit 1;
  • an electroencephalogram (EEG) reporting diagnostic criteria for LGS at some point in their history (abnormal background activity accompanied by slow, spike, and wave pattern <2.5 Hz).
  • Participants must be at least 2 years old at the time of consent.
  • Participants must have been <11 years old at the onset of LGS.
  • Participants must have experienced at least 2 drop seizures per week in the 4-week Baseline Period preceding randomization.
  • Participants must have been receiving 1 to 3 concomitant antiepileptic drugs (AEDs) at a stable dose for at least 30 days before Visit 1 (vagal nerve stimulation (VNS) and ketogenic diet do not count as AEDs).
  • In the investigator's opinion, parents or caregivers must be able to keep accurate seizure diaries.
  • Body weight at least 8 kg.
Exclusion Criteria:
  • Presence of progressive neurological disease
  • Presence of drop seizure clusters where individual seizures cannot be reliably counted (seizure clusters are defined as =2 drop seizures with <5 minutes between any 2 consecutive seizures)
  • Prior treatment with perampanel with discontinuation due to safety issues (related to perampanel)
  • Prior treatment with perampanel must have been discontinued at least 30 days before Visit 1
  • Evidence of clinically significant disease (eg, cardiac, respiratory, gastrointestinal, renal disease, hepatic disease) that in the opinion of the investigator(s) could affect the participant's safety or study conduct
  • Scheduled for epilepsy-related surgery or any other form of surgery during the projected course of the study
  • Ketogenic diet and VNS, unless stable and ongoing, for at least 30 days before Visit 1
  • Treatment with an investigational drug or device in the 30 days before Visit 1
  • Status epilepticus within 12 weeks of Visit 1
  • If felbamate is used as a concomitant AED, participants must be on felbamate for at least 1 year, with a stable dose for 60 days before Visit 1. They must not have a history of white blood cell (WBC) count below =2500/microliters (µL), platelets <100,000/µL, liver function tests (LFTs) >3 times the upper limit of normal (ULN), or other indication of hepatic or bone marrow dysfunction while receiving felbamate.
  • Concomitant use of vigabatrin: participants who took vigabatrin in the past must be discontinued for at least 5 months before Visit 1, and must have documentation showing no evidence of a vigabatrin-associated clinically significant abnormality in an automated visual perimetry test
  • Have had multiple drug allergies or a severe drug reaction to an AED(s), including dermatological (eg, Stevens-Johnson syndrome), hematological, or organ toxicity reactions
  • Evidence of significant active hepatic disease. Stable elevations of liver enzymes, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) due to concomitant medication(s) will be allowed if they are < 3 times the ULN
  • Adrenocorticotropic hormone within the 6 months before Visit 1
  • Had history of anoxic episodes requiring resuscitation within 6 months before Visit 1
  • Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta human chorionic gonadotropin [ß-hCG] with a minimum sensitivity of 25 International Units per Liter (IU/L) or equivalent units of ß-hCG or hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  • Females of childbearing potential who: a. had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of contraception (eg, total abstinence, an intrauterine device, a double-barrier method [such as condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period or for 28 days after study drug discontinuation. Females using hormonal contraceptives containing levogesterol must be on another form of contraception as well. b. Are currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from sexual activity during the study period or for 28 days after study drug discontinuation. c. Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation. (NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal [amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause] or have been sterilized surgically [i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing]).
  • Had intermittent use of benzodiazepine of more than 4 single administrations in the month before Visit 1
  • A prolonged QT/QTc interval (QTc >450 milliseconds [ms]) as demonstrated by a repeated electrocardiogram (ECG)
  • Hypersensitivity to the study drug or any of the excipients
  • Any history of a medical condition or a concomitant medical condition that in the opinion of the investigator(s) would compromise the participant's ability to safely complete the study
  • Known to be human immunodeficiency virus (HIV) positive
  • Active viral hepatitis (B or C) as demonstrated by positive serology at Screening
  • Psychotic disorder(s) or unstable recurrent affective disorder(s) evident by use of antipsychotics or prior suicide attempt(s) within approximately the last 2 years
  • History of drug or alcohol dependency or abuse within approximately the last 2 years; use of illegal recreational drugs
  • Concomitant use of medications known to be inducers of cytochrome P450 (CYP3A) including, but not limited to: rifampin, troglitazone, St. John's Wort, efavirenz, nevirapine, glucocorticoids (other than topical usage), modafinil, pioglitazone, and rifabutin
  • Use of AEDs not recommended by Epilepsy Treatment Guidelines for use in LGS including, but not limited to carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiababine, and vigabatrin
  • Concomitant use of cannabinoids

Contact

Tara McTigue
University of South Florida - South Tampa Center for Advanced Healthcare
2 Tampa General Circle
Tampa, FL 33606
Phone: (813) 259-0826

View Map

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.